WO2018170766A1 - Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application - Google Patents

Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application Download PDF

Info

Publication number
WO2018170766A1
WO2018170766A1 PCT/CN2017/077608 CN2017077608W WO2018170766A1 WO 2018170766 A1 WO2018170766 A1 WO 2018170766A1 CN 2017077608 W CN2017077608 W CN 2017077608W WO 2018170766 A1 WO2018170766 A1 WO 2018170766A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
sirna
application
seq
programmed death
Prior art date
Application number
PCT/CN2017/077608
Other languages
English (en)
Chinese (zh)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2017/077608 priority Critical patent/WO2018170766A1/fr
Publication of WO2018170766A1 publication Critical patent/WO2018170766A1/fr

Links

Definitions

  • the present invention belongs to the field of molecular genetics, and more particularly to a siRN capable of inhibiting human programmed death ligand 2
  • Non-small cell lung cancer is a common malignant tumor in the world, and its incidence is increasing year by year. Studying NSCLC tumor recurrence factors and tumor immune escape mechanisms has important theoretical significance and clinical application value. T lymphocytes are important effector cells that mediate tumor immune responses, and T cell activation requires TCR-mediated antigen-specific signaling and costimulatory molecule-mediated costimulatory signals.
  • PD-L2 Programmed death ligand 2
  • B7-H1 is a negative T cell costimulatory molecule in the B7 family
  • PD-L2 inhibits proliferation of CD4 and CD8 T cells by binding to its receptor PD-1
  • activation negative regulation of the body's immune response process, thereby mediating tumor immune escape, promoting tumor growth
  • the role of PD-L2 in tumor escape has an important role in the prevention and treatment of tumors, but the lack of specificity in the prior art
  • the vector that inhibits the expression of the PD-L2 gene makes the related research not well developed.
  • RNAi small interfering RNA
  • siPDL2 sequence is as follows: [0007] Justice strand: 5,- GAGGGAAGUGAACAGUGCU-3' (SEQ ID NO: l);
  • Antisense strand 5,-AGCACUGUUCACUUCCCUC-3' (SEQ ID NO: 2).
  • 1 is a schematic diagram showing the results of quantitative PCR detection of PD-L2 gene expression levels after HepG2 cells transfected with siPDL2.
  • Total RNA extraction Total RNA of PD-L2 cells normal and transfected with siPDL2 was extracted using the QIAGEN RNeasy Mini Kit.

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un ARNsi capable d'inhiber de manière efficace et spécifique l'expression, au niveau ARNm, d'un gène PD-L2, les séquences de celui-ci étant les suivantes : brin sens : 5'-GAGGGAAGUGAACAGUGCU-3'(SEQ ID NO:1) ; et brin antisens : 5'-AGCACUGUUCACUUCCCUC-3'(SEQ ID NO:2). L'invention concerne également une application de cet ARNsi dans la préparation de médicaments destinés au traitement de maladies associées à une expression anormale du gène PD-L2.
PCT/CN2017/077608 2017-03-22 2017-03-22 Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application WO2018170766A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077608 WO2018170766A1 (fr) 2017-03-22 2017-03-22 Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077608 WO2018170766A1 (fr) 2017-03-22 2017-03-22 Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application

Publications (1)

Publication Number Publication Date
WO2018170766A1 true WO2018170766A1 (fr) 2018-09-27

Family

ID=63584900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/077608 WO2018170766A1 (fr) 2017-03-22 2017-03-22 Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application

Country Status (1)

Country Link
WO (1) WO2018170766A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428179A (zh) * 2009-03-06 2012-04-25 国立大学法人三重大学 用于增强t细胞功能的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428179A (zh) * 2009-03-06 2012-04-25 国立大学法人三重大学 用于增强t细胞功能的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOBO, W. ET AL.: "siRNA silencing of PD - LI and PD - L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD 8+ T cells", BLOOD, vol. 116, no. 22, 25 November 2010 (2010-11-25), pages 4501 - 4511, XP055298201, ISSN: 0006-4971 *
ROZALI, E. N. ET AL.: "Programmed Death Ligand 2 in Cancer-Induced Immune Suppression", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 2012, 31 December 2012 (2012-12-31), pages 1 - 9, XP055539612, ISSN: 1740-2522 *
WANG, GUOYAN ET AL.: "PD-L1/PD-L2 on Human Placenta-Derived Mesenchymal Stem Cells Inhibits the IL 17 Secretion of Peripheral Blood T Cells", CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 29, no. 2, 31 December 2013 (2013-12-31), pages 132 - 136, ISSN: 1007-8738 *
ZHANG, SIYING ET AL.: "PD -Between L2 in Human Placenta Mesenchymal Stem Cells on the Expression and Its Biological Significance", JOURNAL OF HEZE MEDICAL COLLEGE, 31 December 2013 (2013-12-31), ISSN: 1008-4118 *

Similar Documents

Publication Publication Date Title
WO2019000146A1 (fr) Siarn de récepteur de mort cellulaire programmée humaine 1 et son utilisation
JP7017247B2 (ja) がんを処置するための組み合わせベクターおよび方法
JP5902138B2 (ja) 癌治療と幹細胞調節のための方法
Guo et al. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells
JP6081798B2 (ja) ｍｉＲＮＡに関連する癌を検出および処置するための方法および組成物およびｍｉＲＮＡインヒビターおよび標的
You et al. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy
TW200908987A (en) RNA antagonist compounds for the modulation of HER3
CN110804613B (zh) 一种靶向抑制lncRNA-00861基因表达的siRNA在肝癌治疗中的应用
Wu et al. Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells
WO2011021177A2 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
US11013754B2 (en) Compositions and methods for treating cancer
WO2011130426A2 (fr) Compositions et procédés de traitement de mélanome
CA2739948A1 (fr) Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196
Kadota et al. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors
WO2012093384A1 (fr) Compositions et procédés de traitement du cancer de l'ovaire
WO2018170766A1 (fr) Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 2 et son application
WO2019000149A1 (fr) Arnsi du gène humain codant pour le ligand de mort cellulaire programmée 1 et son utilisation
US20170369884A1 (en) MicroRNAs Sensitize Cancers to Therapy
WO2019000148A1 (fr) Arnsi du gène abcb6 humain et utilisation correspondante
KR101042052B1 (ko) 항-ｍｉｃｒｏＲＮＡ를 포함하는 고형암 예방 또는 치료용조성물
US20110117181A1 (en) Treating hepatitis c virus infection with over-expression of microrna-196
KR102069945B1 (ko) EGFRviii 발현을 이용한 신경 줄기세포의 종양화 유도방법
Moriyama et al. Small interfering RNA (siRNA) against the survivin gene increases apoptosis in a canine melanoma cell line
Farhadi et al. Survivin Gene Disruption via CRISPR/Cas9 Induces Apoptosis Through Down-regulation of FBXO5 and RRM2 in Prostate Cancer Cell Line PC3.
Priyadarshini et al. Downregulation of ribosomal RNA (rRNA) genes in human head and neck squamous cell carcinoma (HNSCC) cells correlates with rDNA promoter hypermethylation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17902270

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17902270

Country of ref document: EP

Kind code of ref document: A1